Phaseline

Companies › Xiamen Innovax Biotech

Xiamen Innovax Biotech: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 4; Infectious disease; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) Vacc
9-valent HPV vaccine (recombinant viral-like particles for HPV types 6, 11, 16, 18, 31, 33
–Phase 4Infection by Human Papilloma Virus; HPV InfectionFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07668271Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) VaccPhase 4Infection by Human Papilloma VirusInfectious diseaseFeb 2027
NCT07281677Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) VaccPhase 4HPV InfectionInfectious diseaseDec 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

NPO Petrovax National Vaccine and Serum Institute, China ARJ Medical MAXVAX Biotechnology Limited Liability Company Biothervax

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.